New Drug Offers Hope for Vision Loss in Estonia’s Elderly Population Estonia is facing a significant challenge with age-related macular degeneration, with nearly 45% of individuals over 65 experiencing the condition. The prevalence of this vision impairment has led to a substantial demand for treatment, with over 20,000 eye injections administered annually to slow its progression. A new medication is set to become available in Estonia from April, offering a potential breakthrough in managing the disease. This drug is anticipated to significantly reduce the frequency of required injections, a key factor in the treatment of age-related macular degeneration. Age-related macular degeneration is a leading cause of vision loss among the elderly, impacting a large portion of Estonia’s senior population. Current treatment protocols rely heavily on regular injections to manage the condition and preserve remaining vision. Healthcare professionals and researchers in Estonia are optimistic about the new drug’s potential to improve the quality of life for those affected by this debilitating condition. Further studies are planned to fully assess the drug’s long-term efficacy and impact on the number of injections needed for the elderly. Topics: #injections #elderly #estonia Post navigation The world is moving towards a global energy crisis Respecting history or romanticizing poverty: the most hot trend in interior design is moldy walls
This is a welcome development that could significantly improve the lives of many elderly Estonians. Reply